基本信息
浏览量:337
职业迁徙
个人简介
Prof. Dr. Dr. Torsten Haferlach is CEO of MLL, a central reference laboratory providing diagnostic services for physicians in Germany that processes some 50,000 samples — mostly leukemias, myelodysplastic syndromes, and myeloproliferative neoplasms — each year. Three years ago, the institution adopted next-generation sequencing technologies to help keep up with demand to screen for molecular mutations; today, MLL is one of the largest 454 sequencing labs in Europe with seven instruments in accredited routine operations, and it has added two Illumina MiSeq instruments to its facility since the end of 2011.
According to Dr. Alexander Kohlmann, Laboratory Director for Next-Generation Sequencing at MLL, “The field is evolving to a situation where we’re no longer sequencing single genes but rather panels of genes.” Part of his job is to ensure that the laboratory can keep up with burgeoning demand from its customers. “Doctors are asking for information about many genes in parallel. They want the results for all these markers at the same time and not step by step,” he says, expecting a turn-around time of five to six days from sample receipt to sending out a report.
With that in mind, MLL has been developing a panel of genes linked to myeloid malignancies for research use on the RainDance Technologies targeted sequencing platform, starting with the RDT 1000 and more recently adding the higher-throughput ThunderStorm® instrument released this year.
The panel, which will be commercially available to other RainDance customers, consists of more than 25 genes. Haferlach and his team are targeting genes in which mutations are known to be medically actionable today based on information from scientific publications. “We developed the myeloid panel for research use in those malignancies where a lot of genes are already being requested today or where we see an unmet need to test these genes at a high level of sensitivity and throughput, providing actionable prognostic information to clinicians suitable to guide therapy in the near future,” Haferlach says.
研究兴趣
论文共 976 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
MEDIZINISCHE GENETIKno. 1 (2024): 21-29
Nature Communicationsno. 1 (2024): 1-1
MEDIZINISCHE GENETIKno. 1 (2024): 3-11
Tobias Suske,Helena Sorger,Gabriele Manhart, Frank Ruge,Nicole Prutsch,Mark W Zimmerman,Thomas Eder, Diaaeldin I Abdallah,Barbara Maurer,Christina Wagner,Susann Schönefeldt,Katrin Spirk,
BLOOD ADVANCESno. 3 (2024): 766-779
In Young Choi,Jonathan P. Ling,Jian Zhang,Eric Helmenstine,Wencke Walter, Panagiotis Tsakiroglou, Riley E. Bergman, Celine Phillipe,James L. Manley,Kevin Rouault-Pierre,Bing Li,Daniel H. Wiseman,
Blood Advances (2024)
Caterina Gregorio,Marta Spreafico, Saverio D'Amico, Elisabetta Sauta, Gianluca Asti,Luca Lanino,Cristina Astrid Tentori,Uwe Platzbecker,Torsten Haferlach,Maria Diez-Campelo,Pierre Fenaux,Rami Komrokji,
JCO clinical cancer informaticsno. 8 (2024): e2300205-e2300205
Leukemiapp.1-4, (2024)
Georg Greiner,Nadine Witzeneder,Klara Klein,Simone Tangermann,Petra Kodajova,Eva Jaeger, Franz Ratzinger, Marlene C Gerner,Mohamad Jawhar, Sigrid Baumgartner, Karin Fruehwirth,Klaus G Schmetterer,
Bloodno. 11 (2024): 1006-1017
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn